LG’s Gimiglo to challenge multinational firms

Published: 2012-07-02 06:57:00
Updated: 2012-07-02 06:57:00
The domestic 460-billion won oral diabetes markets may be encountered with a fierce competition between domestic and foreign multinational drug corporations when LG Life Sciences’ diabetes treatment, Gemiglo, jumps in.

The Korea Food and Drug Administration said Wednesday that it has approved ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.